VNRX

VolitionRx Limited

$0.18

-7.80%
SectorHealthcareIndustryMedical DevicesCountryUnited States

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.

Source: Yahoo Finance
AI summary

Price & performance

1M-12.2%
3M-76.1%
YTD-96.6%
1Y-97.6%
52-week range—
Beta0.60
Full chart and returns against a benchmark

Q-Score

4/ 100

Quality against peers; 50 is the peer median.

Growth32
Risk38
Performance16
Valuation14
Profitability7
Leverage4
Sentiment96
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$1.7M+40.0%
Net income-$23.4M
Net margin—
Historical fundamentals

Red flags in filings

3active red flags
Going-concern doubtMar 31, 2026
Material weakness in controlsMar 31, 2026
Exchange listing noticeApr 23, 2026
Filings, findings and the timeline

Revenue exposure

0%of revenue from outside the US
United States100%
Regions, segments, customers and suppliers

Valuation

VNRXIndustryP/E—29.61P/S2.263.49EV/EBITDA—18.38P/B—3.39PEG——
Dividend yield0.00%
Every valuation metric

Earnings

Nov 12next report, after the close
EPS estimate$-0.31
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate